Staidson BioPharm
30020421.974.92% ( +1.03 )
Q1 2026 Earnings
Financial report interval: 2025.12.31 - 2026.03.31
Overview: Staidson BioPharm(300204) the Revenue is 46.9 M (-25.81%);the EBIT is -5.574 M (-41.96%);the EPS is -0.02 (-309.3%).
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
0.05B25.81%
----
----
EBIT
-0.01B41.96%
----
----
EPS
-0.02309.25%
----
----
Revenue
ActualEstimateUnit: CNY
qf
EBIT
ActualEstimateUnit: CNY
qf
Net income
ActualEstimateUnit: CNY
qf
EPS
ActualEstimateUnit: CNY
qf